Clifford S Pukel

Title: The Innovative Contributions of Clifford S. Pukel

Introduction

Clifford S. Pukel is a notable inventor based in Flushing, NY (US). He has made significant contributions to the field of cancer research, particularly through his innovative patent related to melanoma detection. His work has implications for both diagnostics and therapeutic strategies in oncology.

Latest Patents

Clifford S. Pukel holds a patent for a method titled "Method for detecting the presence of G.sub.D3 ganglioside - Mouse monoclonal antibody AbR.sub.24." This patent, published in the Proceedings of the National Academy of Sciences in 1980, describes a highly specific antibody that detects G.sub.D3 ganglioside in human melanoma cells. The antibody, AbR.sub.24, has been shown to react exclusively with G.sub.D3, distinguishing it from other gangliosides. This specificity is crucial for accurately identifying melanoma cells in various tissue samples.

Career Highlights

Pukel's career is marked by his association with the Sloan-Kettering Institute for Cancer Research, where he has conducted extensive research on gangliosides and their role in cancer. His innovative approaches have led to the development of new serological assays, such as the glycolipid-mediated immune adherence (GMIA) assay, which enhances the detection of gangliosides in different cell types.

Collaborations

Throughout his career, Clifford S. Pukel has collaborated with esteemed colleagues, including Kenneth O. Lloyd and Luiz R. Travassos. These collaborations have enriched his research and contributed to advancements in the understanding of gangliosides in cancer biology.

Conclusion

Clifford S. Pukel's contributions to cancer research through his innovative patent and collaborative efforts have significantly advanced the field. His work continues to influence diagnostic methods and therapeutic strategies for melanoma and other cancers.